stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Return on equity
Veracyte, Inc.'s return on equity over the twelve months to 30 September 2026 was 9.43%, up 4.1 percentage points from fiscal 2025 (5.34%). Over the past ten years it has ranged from −72.8% (fiscal 2015) to 5.34% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 5.34% | 3.17 |
| FY2024 | 2.17% | 9.19 |
| FY2023 | −7.02% | (3.65) |
| FY2022 | −3.37% | 6.59 |
| FY2021 | −9.96% | 0.61 |
| FY2020 | −10.6% | (2.68) |
| FY2019 | −7.89% | 31.43 |
| FY2018 | −39.3% | 24.73 |
| FY2017 | −64.1% | (7.46) |
| FY2016 | −56.6% | 16.18 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| SHC Sotera Health Company compare | 27.0% |
| VCYT Veracyte, Inc. | 9.43% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RDNT RadNet, Inc. compare | −1.64% |
| NEO NeoGenomics, Inc. compare | −3.94% |
| GRAL GRAIL, Inc. compare | −17.3% |
| ADPT Adaptive Biotechnologies Corporation compare | −36.3% |
| WGS GeneDx Holdings Corp. compare | −40.8% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement